AU7957000A - Cyclooxygenase-2 expression inhibitors - Google Patents

Cyclooxygenase-2 expression inhibitors

Info

Publication number
AU7957000A
AU7957000A AU79570/00A AU7957000A AU7957000A AU 7957000 A AU7957000 A AU 7957000A AU 79570/00 A AU79570/00 A AU 79570/00A AU 7957000 A AU7957000 A AU 7957000A AU 7957000 A AU7957000 A AU 7957000A
Authority
AU
Australia
Prior art keywords
cyclooxygenase
expression inhibitors
inhibitors
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU79570/00A
Inventor
Hajime Komatsu
Keiji Wakabayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ORGANIZATION FOR PHARMACEUTICAL SAFETY AND RESEARCH
National Cancer Center Japan
Original Assignee
JP AGENCY OF NAT
ORGANIZATION FOR PHARMACEUTICA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JP AGENCY OF NAT, ORGANIZATION FOR PHARMACEUTICA filed Critical JP AGENCY OF NAT
Publication of AU7957000A publication Critical patent/AU7957000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU79570/00A 1999-10-25 2000-10-25 Cyclooxygenase-2 expression inhibitors Abandoned AU7957000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP11/302979 1999-10-25
JP30297999 1999-10-25
PCT/JP2000/007462 WO2001030341A1 (en) 1999-10-25 2000-10-25 Cyclooxygenase-2 expression inhibitors

Publications (1)

Publication Number Publication Date
AU7957000A true AU7957000A (en) 2001-05-08

Family

ID=17915479

Family Applications (1)

Application Number Title Priority Date Filing Date
AU79570/00A Abandoned AU7957000A (en) 1999-10-25 2000-10-25 Cyclooxygenase-2 expression inhibitors

Country Status (2)

Country Link
AU (1) AU7957000A (en)
WO (1) WO2001030341A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5081354B2 (en) * 2001-11-07 2012-11-28 株式会社ナリス化粧品 IgE production inhibitor
US7108868B2 (en) 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
US7972632B2 (en) 2003-02-28 2011-07-05 Unigen Pharmaceuticals, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US8034387B2 (en) 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
CA2484192C (en) 2002-04-30 2012-10-02 Unigen Pharmaceuticals, Inc. Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
BRPI0409179A (en) 2003-04-04 2006-05-02 Unigen Pharmaceuticals Inc formulation of dual cyclooxygenase (cox) and lipoxygenase (lox) inhibitors for mammalian skin care
ES2432747T3 (en) 2003-06-27 2013-12-05 Kyowa Hakko Kirin Co., Ltd. HSP90 family protein inhibitors
KR100761248B1 (en) 2006-10-12 2007-10-04 주식회사 유니젠 Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08157361A (en) * 1994-12-08 1996-06-18 Toyama Chem Co Ltd Selective inhibitor for cyclooxygenase-2 and suppressing agent for cyclooxygenase-2 expression

Also Published As

Publication number Publication date
WO2001030341A1 (en) 2001-05-03

Similar Documents

Publication Publication Date Title
AU2001258771A1 (en) -secretase inhibitors
AU2001244399A1 (en) Gamma-secretase inhibitors
AU2002219555A1 (en) VLA-4 Inhibitors
AU2001280099A1 (en) 4-acylaminopyrazole derivatives
AU2001230584A1 (en) 1h-imidazopyridine derivatives
HK1041407B (en) Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors
AU2001296961A1 (en) 17-beta-hydroxysteroid dehydrogenase-ii inhibitors
AU2001230537A1 (en) Pyridoxazine derivatives
AU2001281802A1 (en) 6-phenylpyrrolopyrimidinedione derivatives
AU2001278790A1 (en) 1h-imidazopyridine derivatives
AU3074500A (en) Proteasome inhibitors
AU1132601A (en) Feature interactions
AU7961300A (en) Kainic acid neurocytotoxicity inhibitors
AU7126900A (en) Enzyme inhibitors
AU3235100A (en) Prothease inhibitors
AU3761400A (en) Amino-thio-acrylonitriles as mek inhibitors
AU6338000A (en) Labeled neurotensin derivatives
AU2001254661A1 (en) Aminosulfonylbiphenyl derivatives
AU2001230565A1 (en) Perfluoroisopropylbenzene derivatives
AU7957000A (en) Cyclooxygenase-2 expression inhibitors
AU1588901A (en) Protease inhibitors
AU7445100A (en) Sebum production inhibitors
AU1474801A (en) Protease inhibitors
AU7593800A (en) Small library works-in-a-drawer
AU2001242772A1 (en) 3-substituted-4-pyrimidone derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase